Payment overview · 2025
General Payments
$516.87
25 reported records · 14 companies
Healthcare provider profile · identity verified
Ernestina T Agresti, DO
Allopathic & Osteopathic Physicians|Family Medicine · ROSEVILLE, CA · NPI 1558432021
Verified facts
What the public records show
CMS Open Payments records show Ernestina T Agresti, DO received $516.87 in general payments during 2025 across 25 reported records.
Lilly USA, LLC accounted for 35.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $181.01 | 35.0% | 6 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $36.61 | 7.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.65 | 6.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.12 | 6.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.00 | 6.0% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.87 | 6.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.60 | 5.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.09 | 5.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.56 | 4.8% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $20.83 | 4.0% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.44 | 3.8% | 1 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $16.34 | 3.2% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $15.41 | 3.0% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $15.34 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $516.87 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $113.53 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.96 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.96 | 4 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $36.61 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $35.65 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.12 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.12 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $31.00 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $30.87 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.60 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.09 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $15.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 555 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 379 | 96 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 264 | 62 |
| Gabapentin | Gabapentin | 259 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 255 | 69 |
| Alprazolam | Alprazolam | 217 | 39 |
| Losartan Potassium | Losartan Potassium | 206 | 52 |
| Lorazepam | Lorazepam | 185 | 35 |
| Trazodone Hcl | Trazodone Hcl | 153 | 35 |
| Morphine Sulfate Er | Morphine Sulfate | 150 | 17 |
| Sertraline Hcl | Sertraline Hcl | 142 | 28 |
| Atorvastatin Calcium | Atorvastatin Calcium | 140 | 46 |
| Omeprazole | Omeprazole | 136 | 35 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 135 | 39 |
| Simvastatin | Simvastatin | 119 | 27 |
| Metformin Hcl | Metformin Hcl | 104 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 98 | 28 |
| Liothyronine Sodium | Liothyronine Sodium | 96 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 96 | 15 |
| Donepezil Hcl | Donepezil Hcl | 95 | 22 |
| Potassium Chloride | Potassium Chloride | 95 | 30 |
| Eliquis | Apixaban | 93 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 89 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 26 |
| Tramadol Hcl | Tramadol Hcl | 87 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 28 |
| Furosemide | Furosemide | 84 | 25 |
| Lisinopril | Lisinopril | 84 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 79 | 17 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 77 | 61 |
| Glimepiride | Glimepiride | 70 | 18 |
| Ozempic | Semaglutide | 70 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 21 |
| Methylprednisolone | Methylprednisolone | 65 | 60 |
| Aripiprazole | Aripiprazole | 64 | 13 |
| Azithromycin | Azithromycin | 63 | 57 |
| Prednisone | Prednisone | 55 | 27 |
| Famotidine | Famotidine | 53 | 17 |
| Mirtazapine | Mirtazapine | 52 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 51 | suppressed |
| Celecoxib | Celecoxib | 50 | 14 |
| Clonazepam | Clonazepam | 50 | suppressed |
| Estradiol | Estradiol | 50 | 20 |
| Mounjaro | Tirzepatide | 50 | 14 |
| Montelukast Sodium | Montelukast Sodium | 49 | 13 |
| Allopurinol | Allopurinol | 46 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | 15 |
| Atenolol | Atenolol | 43 | suppressed |
| Meloxicam | Meloxicam | 41 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 40 | suppressed |
| Finasteride | Finasteride | 39 | suppressed |
| Glipizide | Glipizide | 38 | suppressed |
| Valsartan | Valsartan | 38 | 12 |
| Baclofen | Baclofen | 37 | suppressed |
| Eszopiclone | Eszopiclone | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Ibuprofen | Ibuprofen | 36 | 15 |
| Ondansetron Odt | Ondansetron | 36 | 22 |
| Valacyclovir | Valacyclovir Hcl | 36 | 22 |
| Buprenorphine | Buprenorphine | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 11 |
| Pregabalin | Pregabalin | 35 | suppressed |
| Testosterone | Testosterone | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | 11 |
| Hydromorphone Hcl | Hydromorphone Hcl | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 21 |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 17 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Nystatin | Nystatin | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | 15 |
| Carisoprodol | Carisoprodol | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 13 |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | 16 |
| Spironolactone | Spironolactone | 18 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 16 | 12 |
| Lovastatin | Lovastatin | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $516.87 · 25 records | Lilly USA, LLC | BREZTRI, Cologuard Collection Kit, DUPIXENT, EMGALITY, GLYCATE, JOURNAVX, KISUNLA, MOUNJARO, NUZYRA, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, SPRAVATO, TRELEGY ELLIPTA, UBRELVY, ZENPEP, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error